News Release 

Study explains the process that exacerbates MS

Karolinska Institutet

Research News

IMAGE

IMAGE: Research group, from the left: André Ortlieb Guerreiro-Cacais (researcher), Maja Jagodic (docent and group leader for research on MS epigenetics), Rasmus Berglund (doctoral student), and Tomas Olsson (professor). view more 

Credit: Ulf Sirborn

People with multiple sclerosis (MS) gradually develop increasing functional impairment. Researchers at Karolinska Institutet have now found a possible explanation for the progressive course of the disease in mice and how it can be reversed. The study, which is published in Science Immunology, can prove valuable to future treatments.

MS is a chronic inflammatory disease of the central nervous system (CNS) and one of the main causes of neurological functional impairment.

The disease is generally diagnosed between 20 and 30 years of age. It can cause severe neurological symptoms, such as loss of sensation and trembling, difficulties walking and maintaining balance, memory failure and visual impairment.

MS is a life-long disease with symptoms that most often gradually worsen over time.

In the majority of cases the disease comes in bouts with a certain amount of subsequent recovery. A gradual loss of function with time is, however, inevitable. Research has made great progress in treatments that reduce the frequency and damaging effects of these bouts.

"Despite these important breakthroughs, the disease generally worsens when the patient has had it for 10 to 20 years," says Maja Jagodic, docent of experimental medicine at the Department of Clinical Neuroscience and the Centre for Molecular Medicine, Karolinska Institutet. "There is currently only one, recently approved, treatment for what is called the secondary progressive phase. The mechanisms behind this progressive phase require more research."

Researchers at Karolinska Institutet have now shown that recovery from MS-like symptoms in mice depends on the ability of the CNS's own immune cells - microglia - to break down the remains of damaged cells, such as myelin.

The processes was interrupted when the researchers removed a so-called autophagy gene, Atg7. Autophagy is a process where cells normally break down and recycle their own proteins and other structural components.

Without Atg7 the ability of the microglia to clean away tissue residues created by the inflammation was reduced. These residues accumulated over time, which is a possible explanation for the progressiveness of the disease.

The study also shows how microglia from aged mice resemble the cells from young mice that lacked Atg7 in terms of deficiencies in this process, which had a negative effect on the course of the disease.

This is a significant result since increasing age is an important risk factor in the progressive phase of MS. The researchers also show how this process can be reversed.

"The plant and fungi-derived sugar Trehalose restores the functional breakdown of myelin residues, stops the progression and leads to recovery from MS-like disease." says doctoral student Rasmus Berglund. "By enhancing this process we hope one day to be able to treat and prevent age-related aspects of neuroinflammatory conditions."

###

The research was carried out with grants from the Swedish Research Council, the Swedish Brain Foundation, Neuro, Region Stockholm, Astra Zeneca, Horizon 2020, the European Research Council, the Knut and Alice Wallenberg Foundation, the Margaretha af Uggla Foundation, Alltid Litt Sterkere, the Foundation of Swedish MS research, NEURO Sweden and Karolinska Institutet. There are no declared conflicts of interest.

Publication: "Microglial autophagy-associated phagocytosis is essential for recovery from neuroinflammation". Rasmus Berglund, Andre Ortlieb Guerreiro-Cacais, Milena Z. Adzemovic, Manuel Zeitelhofer, Harald Lund, Ewoud Ewing, Sabrina Ruhrmann, Erik Nutma, Roham Parsa, Melanie Thessen-Hedreul, Sandra Amor, Robert A. Harris, Tomas Olsson and Maja Jagodic. Science Immunology, 16 October 2020, doi: 10.1126/sciimmunol.abb5077.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.